Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 14/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468331 | 0.89 | TLR7 (0.45) | PDE8B | |
| SCHEMBL19423854 | 0.85 | PDE8B (0.47) | PDE8BMAPK1CNR1CNR2 | |
| SCHEMBL5731724 | 0.85 | PDE8B (0.47) | PDE8BMAPK1CNR1CNR2 | |
| SCHEMBL18431198 | 0.85 | PDE8B (0.47) | PDE8BMAPK1CNR1CNR2 | |
| SCHEMBL2060546 | 0.82 | MAPK1 (0.38) | ITGB3ITGA2BMAPK1 | |
| SCHEMBL10309736 | 0.82 | TLR7 (0.44) | ITGB3ITGA2B | |
| SCHEMBL5472433 | 0.82 | TLR7 (0.40) | ITGB3ITGA2B | |
| SCHEMBL5730647 | 0.81 | PDE8B (0.50) | PDE8BMAPK1 | |
| SCHEMBL5468415 | 0.81 | TLR7 (0.41) | — | |
| SCHEMBL5457974 | 0.81 | TLR7 (0.42) | ITGB3ITGA2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | claimed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | claimed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | PDE8B 431/4885ITGB3 3332/4885ITGA2B 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.